A recombinant humanized monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab contains human framework regions and the complementarity-determining regions of a murine antibody that binds to VEGF. Bevacizumab is produced in a Chinese Hamster Ovary mammalian cell expression system in a nutrient medium containing the antibiotic gentamicin and has a molecular weight of approximately 149 kilodaltons.

Price Not Available 1 mg Bevacizumab Supplier Page
Trivial name Bevacizumab
Catalog Number TP-078CL
Alternative Name(s) Bevacizumab
Research Area Cancer
Molecular Formula C6538H10034N1716O2033S44
CAS# 216974-75-3
Purity >90%
Size 1 mg
Supplier Page
Additional Information As part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer.